Kalaris Therapeutics, Inc.
KLRS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001754068
No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Kalaris Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 84 | 2 | 84 | +2 |
| Shares | 27.3M | 23.6K | 28.1M | +864.7K (+3.2%) |
| Value | $184.1M | $160.0K | $109.6M | −$74.3M (−40.4%) |
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (14)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Regency Capital Management Inc. | 75,000 | $292.0K | 0.31% |
| Cornercap Investment Counsel Inc | 33,579 | $131.0K | 0.02% |
| Ergoteles LLC | 28,400 | $111.0K | 0.00% |
| Bailard, Inc. | 21,900 | $85.0K | 0.00% |
| Prudential Financial Inc | 17,000 | $66.0K | 0.00% |
| Trexquant Investment LP | 15,172 | $59.0K | 0.00% |
| HSBC Holdings PLC | 14,744 | $56.0K | 0.00% |
| Virtu Financial LLC | 14,120 | $55.0K | 0.00% |
| XTX Topco Ltd | 12,816 | $50.0K | 0.02% |
| SG Americas Securities, LLC | 12,681 | $49.0K | 0.00% |
| Occudo Quantitative Strategies LP | 12,239 | $48.0K | 0.00% |
| Delphia (USA) Inc. | 11,282 | $44.0K | 0.03% |
| Corton Capital Inc. | 10,496 | $41.0K | 0.04% |
| Cutler Group LP | 2,688 | $10.0K | 0.00% |
Sold out (12)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ra Capital Management, L.P. | 1,440,525 | $9.72M |
| Citadel Advisors LLC | 108,945 | $736.0K |
| Man Group plc | 39,151 | $264.0K |
| MetLife Investment Management | 18,052 | $121.9K |
| Manufacturers Life Insurance Company, The | 13,444 | $90.7K |
| Handelsbanken Fonder AB | 13,400 | $90.0K |
| ProShare Advisors LLC | 12,293 | $84.0K |
| Virtus ETF Advisers LLC | 10,463 | $71.0K |
| Quantbot Technologies LP | 2,347 | $15.0K |
| Metropolitan Life Insurance Co | 1,980 | $13.4K |
| Lindbrook Capital, LLC | 268 | $2.00K |
| State of Wyoming | 318 | $2.00K |
Not filed for Q2 2022 yet (2)
Institutions that held Kalaris Therapeutics, Inc. at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Susquehanna Fundamental Investments, LLC | 18,778 | $127.0K |
| Amalgamated Financial Corp. | 4,817 | $33.0K |